Table 2.
Pre-radiotherapy clinical characteristics
| N | Median | |
|---|---|---|
| PSA, median (ng/ml) | 34 | 5.4 |
| Gleason score | N | % |
| 4 | 1 | 2 |
| 5 | 2 | 5 |
| 6 | 12 | 29 |
| 7 | 16 | 39 |
| 8 | 3 | 7 |
| Unknown | 7 | 17 |
| Clinical stage | ||
| T1c | 10 | 24 |
| T2a | 6 | 14 |
| T2b | 5 | 12 |
| T2c | 2 | 5 |
| cT2 | 1 | 2 |
| T2-T3 | 1 | 2 |
| T3a | 1 | 2 |
| Unknown | 15 | 37 |
Pre-radiotherapy clinical characteristics
| N | Median | |
|---|---|---|
| PSA, median (ng/ml) | 34 | 5.4 |
| Gleason score | N | % |
| 4 | 1 | 2 |
| 5 | 2 | 5 |
| 6 | 12 | 29 |
| 7 | 16 | 39 |
| 8 | 3 | 7 |
| Unknown | 7 | 17 |
| Clinical stage | ||
| T1c | 10 | 24 |
| T2a | 6 | 14 |
| T2b | 5 | 12 |
| T2c | 2 | 5 |
| cT2 | 1 | 2 |
| T2-T3 | 1 | 2 |
| T3a | 1 | 2 |
| Unknown | 15 | 37 |